Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

No new drug, just data: large european study to map myelofibrosis outcomes

NCT ID NCT06533813

Knowledge-focused Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This is an observational study that will follow about 617 people with myelofibrosis across Europe. Researchers will collect information from medical records to see how the disease progresses and how patients respond to standard treatments. No experimental drug or intervention is being tested. The goal is to better understand the disease and improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 617 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a 2016- or 2022-WHO confirmed diagnosis of MF established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Patients with primary and secondary to ET and PV myelofibrosis, annotated for genetic and histological features, in relation to the presence of baseline (i.e., at MF diagnosis) or treatment-related cytopenias (i.e., reduced count of blood cells manifesting as anemia, thrombocytopenia and/or neutropenia).

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of primary myelofibrosis (PMF) or secondary (i.e., post-ET/PV MF) myelofibrosis according to 2016- or 2022-WHO criteria ascertained between 01/01/2018 and 31/12/2027 * Age ≥ 18 years * Signed informed consent where applicable, in line with current European General Data Protection Regulation (GDPR) directives Exclusion Criteria: * Diagnosis of early/prefibrotic primary myelofibrosis * Concurrent participation to interventional clinical trials in MF

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myelofibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myelofibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    27 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia U

    NOT_YET_RECRUITING

    Torino, 10126, Italy

  • A.S.O. SS. Antonio e Biagio e C.Arrigo, SC Ematologia

    RECRUITING

    Alessandria, 15121, Italy

  • AOU Careggi di Firenze, Divisione di Ematologia

    RECRUITING

    Florence, Italy

  • ASST Grande Ospedale Metropolitano Niguarda, Divisione di Ematologia

    RECRUITING

    Milan, Italy

  • ASST Papa Giovanni XXIII, SC Ematologia

    RECRUITING

    Bergamo, Italy

  • Azienda Ospedaliera Universitaria Federico II, Divisione di Ematologia

    RECRUITING

    Naples, Italy

  • Azienda Ospedaliera Universitaria Integrata - Ospedale Borgo Roma, Unità di Ematologia

    RECRUITING

    Verona, Italy

  • Azienda Ospedaliero - Universitaria "Policlinico Vittorio Emanuele" - PO Gaspare Rodolico, Dipartimento di ematologia con Trapianto di midollo Osseo

    RECRUITING

    Catania, Italy

  • Azienda Ospedaliero Universitaria Maggiore della Carità, SCDU Ematologia

    RECRUITING

    Novara, Italy

  • Azienda ULSS 8 Berica - Ospedale San Bortolo, Divisione di Ematologia

    RECRUITING

    Vicenza, Italy

  • Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University

    RECRUITING

    Wroclaw, Poland

  • Department of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute

    RECRUITING

    Bucharest, Romania

  • Department of Hematology, University Hospital, Jagiellonian University Medical College

    RECRUITING

    Krakow, Poland

  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Ematologia

    RECRUITING

    Milan, Italy

  • Fondazione IRCCS Policlinico San Matteo, Divisione di Ematologia

    RECRUITING

    Pavia, Italy

  • Fondazione IRCCS San Gerardo dei Tintori

    RECRUITING

    Monza, Italy

  • Fondazione Policlinico Universitario A. Gemelli - Università Cattolica del Sacro Cuore, UCSC Ematologia

    RECRUITING

    Roma, Italy

  • Hematology Center after Prof.R.H. Yeolyan

    RECRUITING

    Yerevan, Armenia

  • Hematology and Hemotherapy Department, 12 de Octubre University Hospital

    RECRUITING

    Madrid, Spain

  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) - Hospital Clinic

    RECRUITING

    Barcelona, Spain

  • Ospedale Cardinale G. Panico

    NOT_YET_RECRUITING

    Tricase, Italy

  • Ospedale San Raffaele, Unità Operativa di Ematologia e Trapianto Midollo Osseo

    RECRUITING

    Milan, Italy

  • Policlinico S. Orsola - Malpighi, Unità di Ematologia

    RECRUITING

    Bologna, Italy

  • Policlinico Umberto I, Dipartimento Ematologia, Oncologia e Dermatologia

    RECRUITING

    Roma, Italy

  • University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center Minden UKRUB, University of Bochum

    RECRUITING

    Minden, Germany

  • University Hospital Halle Department of Hematology/Oncology

    NOT_YET_RECRUITING

    Halle, Germany

  • University Medicine Hannover

    RECRUITING

    Hanover, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.